Your browser doesn't support javascript.
loading
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
van Rossum, A G J; Kok, M; van Werkhoven, E; Opdam, M; Mandjes, I A M; van Leeuwen-Stok, A E; van Tinteren, H; Imholz, A L T; Portielje, J E A; Bos, M M E M; van Bochove, A; Wesseling, J; Rutgers, E J; Linn, S C; Oosterkamp, H M.
Afiliação
  • van Rossum AGJ; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Kok M; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • van Werkhoven E; Biometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Opdam M; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Mandjes IAM; Data Centre, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • van Leeuwen-Stok AE; Dutch Breast Cancer Research Group, BOOG Study Centre, IJsbaanpad 9-11, 1076 CV, Amsterdam, The Netherlands.
  • van Tinteren H; Biometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Imholz ALT; Department of Medical Oncology, Deventer Ziekenhuis, Nico Bolkesteinlaan 75, 7416 SE, Deventer, The Netherlands.
  • Portielje JEA; Department of Medical Oncology, HagaZiekenhuis, Els Borst-Eilersplein 275, 2545 AA, The Hague, The Netherlands.
  • Bos MMEM; Department of Internal Oncology, Reinier de Graaf Gasthuis, Reinier de Graafweg 5, 2625 AD, Delft, The Netherlands.
  • van Bochove A; Department of Medical Oncology, Zaans Medisch Centrum, Koningin Julianaplein 58, 1502 DV, Zaandam, The Netherlands.
  • Wesseling J; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Rutgers EJ; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Linn SC; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Department of Pathology, University Medical Centre, Heidelberglaa
  • Oosterkamp HM; Department of Medical Oncology, Haaglanden Medisch Centrum, The Hague, The Netherlands.
Eur J Cancer ; 102: 40-48, 2018 Oct.
Article em En | MEDLINE | ID: mdl-30125761
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Ciclofosfamida País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Ciclofosfamida País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda